Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients

被引:0
|
作者
Horesh, Adi [1 ]
Pollack, Rena [1 ,2 ]
Nechushtan, Hovav [1 ,3 ]
Dresner-Pollak, Rivka [1 ,2 ]
Neuman, Tzahi [1 ,4 ]
机构
[1] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[2] Hadassah Hebrew Univ, Med Ctr, Dept Endocrinol & Metab, Jerusalem, Israel
[3] Hadassah Hebrew Univ, Med Ctr, Dept Oncol, Jerusalem, Israel
[4] Hadassah Hebrew Univ, Med Ctr, Dept Pathol, Jerusalem, Israel
关键词
PD-L1; NSCLC; immune checkpoint inhibitors; immune-related adverse events; thyroid; ADVERSE EVENTS; NIVOLUMAB; PEMBROLIZUMAB; ANTIBODIES; TSH; P53;
D O I
10.3389/pore.2023.1610951
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 expression and molecular profile with the development of thyroid IRAEs in NSCLC patients.Methods: Single center, retrospective study including 107 NSCLC patients treated with PD-1/PD-L1 inhibitors from April 2016 to July 2020. All patients were euthyroid at baseline with at least two TSH measurements post-treatment initiation. The primary outcome was the difference in tumor PD-L1 expression in patients who developed any thyroid IRAEs versus those who remained euthyroid. Additional outcomes included development of overt thyroid dysfunction, the association of specific molecular alterations with thyroid IRAEs, and onset of thyroid IRAEs as a function of tumor PD-L1 expression.Results: Overall, 37 (34.6%) patients developed any thyroid dysfunction and 18 (16.8%) developed overt thyroid dysfunction. Tumor PD-L1 staining intensity was not associated with thyroid IRAEs. TP53 mutation was less likely to be associated with any thyroid dysfunction (p < 0.05) and no association was found between EGFR, ROS, ALK or KRAS mutations. There was no association between PD-L1 expression and time to develop thyroid IRAEs.Conclusion: PD-L1 expression is not associated with the development of thyroid dysfunction in advanced NSCLC patients treated with ICIs, suggesting that thyroid IRAEs are unrelated to tumor PD-L1 expression.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor
    Kennedy, Laura C.
    Lu, Jun
    Kuehn, Sydney
    Ramirez, Arturo B.
    Lo, Edward
    Sun, Yao
    U'Ren, Lance
    Chow, Laura Q. M.
    Chen, Zhengjia
    Grivas, Petros
    Kaldjian, Eric P.
    Gadi, Vijayakrishna K.
    TARGETED ONCOLOGY, 2022, 17 (03) : 329 - 341
  • [22] Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor
    Laura C. Kennedy
    Jun Lu
    Sydney Kuehn
    Arturo B. Ramirez
    Edward Lo
    Yao Sun
    Lance U’Ren
    Laura Q. M. Chow
    Zhengjia Chen
    Petros Grivas
    Eric P. Kaldjian
    Vijayakrishna K. Gadi
    Targeted Oncology, 2022, 17 : 329 - 341
  • [23] Patterns of PD-L1 expression and tumor infiltrating immune cells in resected NSCLC
    Gureviciene, Giedre
    Matulione, Jurgita
    Poskiene, Lina
    Miliauskas, Skaidrius
    Zemaitis, Marius
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [24] Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
    Yanling Wang
    Xiaoping Ma
    Jia Ma
    Jing Li
    Zhiyi Lin
    Wei Gao
    Ping Gong
    Ping Dai
    BMC Cancer, 25 (1)
  • [25] Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report
    Fan, Shanmin
    Yuan, Yang
    Su, Yanfang
    Sang, Die
    SAGE OPEN MEDICAL CASE REPORTS, 2025, 13
  • [26] PD-L1 Expression in Tumor Infiltrating Immune Cells Determined by Digital Imaging Is Associated with Poor Survival in NSCLC Patients
    Asuncion, Bernadette G. Reyna
    Fazreen, Zul
    Omar, Mohd Feroz Mohd
    Salleh, Nur Lina Mohd
    Rozario, Michelle Ann
    Nga, Min-En
    Pang, Yin Huei
    Pang, Brendan
    Loh, Marie
    Cho, Byoung Chul
    Iacopetta, Barry
    Soong, Richie
    Soo, Ross
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S600 - S600
  • [27] Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
    Boeri, Mattia
    Milione, Massimo
    Proto, Claudia
    Signorelli, Diego
    Lo Russo, Giuseppe
    Galeone, Carlotta
    Verri, Carla
    Mensah, Mavis
    Centonze, Giovanni
    Martinetti, Antonia
    Sottotetti, Elisa
    Pastorino, Ugo
    Garassino, Marina Chiara
    Sozzi, Gabriella
    CLINICAL CANCER RESEARCH, 2019, 25 (07) : 2166 - 2173
  • [28] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Kuska, Katarzyna
    Skalniak, Lukasz
    Grudnik, Przemyslaw
    Musielak, Bogdan
    Plewka, Jacek
    Kocik, Justyna
    Stec, Malgorzata
    Weglarczyk, Kazimierz
    Sala, Dominik
    Wladyka, Benedykt
    Siedlar, Maciej
    Holak, Tad A.
    Dubin, Grzegorz
    ADVANCED THERAPEUTICS, 2021, 4 (02)
  • [29] Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
    Ruiting Li
    Xiaojing Zou
    Huaqing Shu
    You Shang
    Intensive Care Research, 2021, 1 (1-2): : 11 - 15
  • [30] Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
    Masuda, K.
    Horinouchi, H.
    Tanaka, M.
    Higashiyama, R.
    Shinno, Y.
    Sato, J.
    Yoshida, T.
    Matsumoto, Y.
    Goto, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S292 - S293